MIRA Pharmaceuticals, a US-based clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, has announced that its stockholders have approved the acquisition of SKNY Pharmaceuticals at the company’s 2025 Annual Meeting of Stockholders. The deal is expected to close soon, subject to customary closing conditions.

The transaction strengthens MIRA’s pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30 percent weight loss and nicotine craving reversal in preclinical studies.

"We believe SKNY-1 could be a best-in-class oral therapy for two of the leading causes of preventable death – obesity and nicotine addiction. Our shareholders' approval is a major milestone that positions us to close the SKNY acquisition and advance this programme toward IND-enabling studies," said Erez Aminov, Chief Executive Officer of MIRA.

Under the terms of the agreement, the transaction will be structured as a share exchange, with SKNY shareholders receiving MIRA common stock in return for their SKNY shares. At closing, SKNY will also contribute USD 5 million in assets or cash (or a combination thereof) to MIRA, strengthening the company’s financial position.

Independent third-party valuation analyses conducted by Moore Financial Consulting assigned an enterprise value of approximately USD 30.5 million to SKNY (based on a risk-adjusted net present value of SKNY-1) and USD 30 million to MIRA, supporting a combined enterprise value of more than USD 60 million for the merged entity.

Dr. Itzchak Angel, Chief Scientific Advisor at MIRA, added, "SKNY-1 has a unique profile with biased CB1 signaling and a unique CB2 profile, and our preclinical data now confirm it can reduce cravings, lower weight and metabolic parameters, and reverse CB1-agonist induced anxiety-addressing the very limitations that halted earlier drugs in this class.”